Vertex's tezacaftor/ivacaftor meets in Phase III for pediatric CF

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said tezacaftor/ivacaftor met the primary endpoint of improving the absolute change in lung clearance index in a double-blind, European and Australian Phase III trial to treat children with cystic fibrosis.

In 54 patients ages 6-11 with CF who have either two copies of the ΔF508 mutation or one copy of the ΔF508 mutation and one residual function mutation, tezacaftor/ivacaftor led to a mean within-group absolute improvement in lung clearance index of 0.51 points through week 8 (p<0.0001)...